Bextra Decision Shows Effort To Improve Drug Safety Transparency, FDA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Announcement about the Bextra withdrawal and the addition of "black box" warnings to all prescription NSAIDs was part of FDA's ongoing effort "to improve communication about emerging drug safety concerns," CDER Acting Deputy Director Throckmorton says.
You may also be interested in...
Bextra Pulled From Market, But Pfizer Hopes To Explore Other Options
Pfizer is characterizing FDA's request for a withdrawal of Bextra as a "marketing suspension"; the company hopes to continue discussions on how valdecoxib could re-enter the market. Increased cardiovascular risk plus a "special risk" of serious skin reactions led FDA to recommend pulling the COX-2 inhibitor.
“Drug Watch” Website Included In FDA’s Rx Safety Reforms
FDA will launch a Drug Watch website as part of its drug safety reform initiative
NME Slowdown Shows Market Pressure On Me-Toos, Not FDA Caution – Lutter
DURHAM, N.C. - The decline in FDA's tally of new molecular entity approvals stems from fewer approvals of non-innovative products in recent years, while approvals of truly innovative products has largely held steady, according to FDA Deputy Commissioner for Policy, Planning and Preparedness Randall Lutter